BC Week In Review | Aug 9, 2010
Clinical News

Axxess drug eluting stent regulatory update

Devax received CE Mark approval in the EU for its Axxess biolimus A9-eluting stent to treat coronary bifurcations. Devax has rights to biolimus A9 from Biosensors International Group Ltd. (SGX:B20, Singapore). Devax Inc. , Lake Forest,...
BC Week In Review | Dec 24, 2007
Clinical News

Axxess drug eluting stent: Completed enrollment in trial

Devax completed enrollment of 302 patients in the international DIVERGE trial. Devax Inc. , Lake Forest, Calif.   Product: Axxess drug eluting stent   Business: Cardiovascular   Molecular target: Not applicable   Description: Biolimus-eluting bifurcation stent...
BC Week In Review | Jun 26, 2006
Clinical News

Axxess drug eluting stent update

Devax started the international DIVERGE trial in up to 600 patients. Devax Inc. , Irvine, Calif.   Product: Axxess drug eluting stent   Business: Cardiovascular   Molecular target: Not applicable   Description: Biolimus eluting bifurcation stent...
Items per page:
1 - 3 of 3